Will Shareholders Support The Bristol/Celgene Merger? – An Informa Pharma Intelligence Podcast

Expectations that the $74bn deal will go through are now reinforced by proxy advisor recommendations that shareholders vote in favor of the transaction. Podcast discussion also includes Karyopharm’s selinexor and J&J’s Spravato.